HR
ELDN icon

Hayden Royal’s Eledon Pharmaceuticals ELDN Stock Holding History

Hayden Royal’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-556
Closed -$6K – 230
2019
Q3 		$6K Buy
+556
New +$7.99K 0.01% 165

Other funds holding ELDN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Hayden Royal's ELDN Position: Q4 2019 in Review

Hayden Royal sold out of Eledon Pharmaceuticals (ELDN) in Q4 2019, closing a stake of 556 shares — an estimated $6K sold.

Hayden Royal first reported a position in ELDN in Q3 2019 and held it in 1 quarter. The position peaked at $6K in Q3 2019. 10 funds tracked by Wall St. Rank hold ELDN as of Q4 2019.

  • Hayden Royal reported no remaining Eledon Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Hayden Royal sold 556 Eledon Pharmaceuticals shares in Q4 2019, an estimated $6K.
  • Hayden Royal first reported a position in Eledon Pharmaceuticals in Q3 2019 and held it in 1 quarter.
  • Hayden Royal's Eledon Pharmaceuticals position peaked at $6K in Q3 2019.
  • 10 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q4 2019.

Based on Hayden Royal's 13F filing for Q4 2019, filed 24 Feb 2020.